DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for apocrine adenocarcinoma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleApocrine adenocarcinoma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for apocrine adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
What the evidence adds up to
Primary orbital apocrine adenocarcinoma is a rare malignant neoplasm. A 61-year-old male with this diagnosis underwent right orbital exenteration, neck dissection, and adjuvant radiotherapy. The authors note that orbital exenteration is commonly performed as the primary intervention, but the role of adjuvant radiotherapy in preventing local recurrence is unclear and should be determined case by case. No survival or response data are given.
Apocrine adenocarcinoma arises mostly in apocrine-dense regions. Local recurrence and locoregional nodal metastasis are often observed, and most patients relapse at regional lymph nodes within five years. One 2020 case report describes a cutaneous apocrine adenocarcinoma that metastasised to a lymph node more than ten years after surgery, illustrating that late relapse is possible.
A 1992 case describes an 81-year-old man with an asymptomatic tumour in the right axilla for three years. Diagnosis was made on histopathological and enzyme histochemical grounds, showing decapitation secretion, PAS-positive diastase-resistant granules, and strong activity of apocrine enzymes such as acid phosphatase and beta-glucuronidase. No treatment outcome or follow-up is reported.
No drug therapy is mentioned in any of these abstracts. What is missing is any prospective trial, any systemic treatment data, any biomarker or molecular stratification, and any funding for a disease so rare that only single-case reports exist.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Orbit · 2024 · 5 citations · open access
Primary orbital apocrine adenocarcinoma: case report and literature review
AbstractPrimary apocrine adenocarcinoma (PAA) originating from the orbit is a rare malignant neoplasm. We present the case of a 61-year-old-male with PAA of the orbit. The patient underwent a right orbital exenteration, neck dissection, and adjuvant radiotherapy. Orbital exenteration is commonly performed as the primary intervention for PAA of the orbit. The role of adjuvant radiotherapy to prevent local recurrence is unclear and may be determined on a case-by-case basis.
Journal of Cutaneous Immunology and Allergy · 2020 · 0 citations · open access
AbstractApocrine adenocarcinoma is a rare malignant neoplasm arising mostly in apocrine-dense regions. Local recurrence and locoregional nodal metastasis are often observed, and most patients relapse at regional lymph nodes within 5 years. Here, we report a very rare case of cutaneous apocrine adenocarcinoma that metastasized to the lymph node more than 10 years after surgery.
AbstractA case of apocrine adenocarcinoma is reported. The patient was a 81-year old man who had an asymptomic tumor for three years in his right axillary cavity. From the histopathological and enzyme histochemical examination of the tumor, we diagnosed this tumor as apocrine adenocarcinoma. The following points were distinct for the case; (1) Its clinical course and the location of lesion were typical. (2) Histologically, decapitation secretion was found evidently in the tumor cells that were arranging in adenoid pattern. (3) The cytoplasma of the tumor cells contained PAS-positive, diastase-resistant granules. (4) The tumor cells show strong activity of apocrine enzymes, such as acid phosphatase and beta-glucuronidase.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
